Other News

Endologix, Inc. to Announce Fourth Quarter and Fiscal Year 2017 Financial Results on February 21, 2018

IRVINE, Calif.–(BUSINESS WIRE)– Endologix Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the fourth quarter and fiscal year 2017 after the market close on Wednesday, February 21, 2018. The Company’s management will host a conference call at 4:30 […]

Stryker’s Wingspan Stent Impresses in Post-Market Study

KALAMAZOO, Michigan, USA, Jan. 25, 2018 /PRNewswire/ — Yesterday the American Heart Association and American Stroke Association updated the ischemic stroke guidelines. The new recommendation expanded the treatment window from six to 16 hours based on overwhelming clinical evidence from the Stryker-sponsored DAWN Trial and confirmed by DEFUSE 3. The guidelines state that […]

CorInnova Selected to Present at “STS/AATS Tech-Con 2018” – Sixth Honor in Five Months

HOUSTON–(BUSINESS WIRE)– CorInnova, an emerging medical device company developing breakthrough technology for the treatment of Heart Failure, announced today that it has been selected to present at the Society for Thoracic Surgeons (STS) / American Association for Thoracic Surgery (AATS) Tech-Con 2018 event to be held this coming Saturday, Jan. 27, […]

Advanced Bifurcation Systems Appoints Industry Veteran Thomas O’Neill to Board of Directors

LOS ANGELES, Jan. 25, 2018 (GLOBE NEWSWIRE) — Advanced Bifurcation Systems (“ABS” or the “Company”), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of current approaches for the treatment of bifurcation lesions in coronary angioplasties, today announced the addition of Thomas O’Neill to the Board […]

REVA Announces First Implant of the Fantom Bioresorbable Scaffold in Italy

SAN DIEGO, Jan. 24, 2018 (GLOBE NEWSWIRE) — REVA Medical Inc.(ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of the Fantom bioresorbable scaffold (“BRS”) in Italy. The procedure was conducted by Dr. Bernardo Cortese at the Fatebenefratelli Hospital in Milan. “Fantom […]

TOBA II BTK Trial Enrollment Ahead of Schedule for the Tack Endovascular System® in Below the Knee Disease

WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) clinical trial surpassed the 100 patient milestone, advancing enrollment well ahead of schedule. The TOBA II BTK is a prospective, […]

ASPIRATION FIRST APPROACH WITH PENUMBRA SYSTEM DEMONSTRATES FAVORABLE OUTCOMES FOR ACUTE ISCHEMIC STROKE

Results of the PROMISE Study Presented at International Stroke Conference LOS ANGELES – January 25, 2018 – Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced results of the company-sponsored PROMISE Study, demonstrating real-world safety and efficacy of the Penumbra System with ACE™68 and ACE™64 […]

MIVI Neuroscience Selects Bob Colloton To Lead Worldwide Commercialization Of Innovative Treatment Solution For Ischemic Stroke

EDEN PRAIRIE, Minn., Jan. 23, 2018 /PRNewswire/ — MIVI Neuroscience, a company dedicated to developing best-in-class treatment solutions to improve clinical outcomes for stroke patients, today announced that Bob Colloton has joined the company’s senior management team as Chief Commercial Officer. Bob brings 27 years of proven experience in medical device sales and market development […]

Boston Scientific Announces Investment and Acquisition Option Agreement with Millipede, Inc.

MARLBOROUGH, Mass., Jan. 24, 2018 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has closed an investment and entered into an acquisition option agreement with Millipede, Inc., a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation (MR). Under the terms of the […]